Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

 

• Merrimack Pharmaceuticals Inc's 
  MACK-14.5%+ Free Alerts
   partner announced that Ipsen SA 
  IPSEY
   reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). 
• The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan. 
• However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. 
• The safety and tolerability of Onivyde were consistent with its already-known safety profile, and no new safety concerns emerged. 
• The clinical study results will be communicated with the regulatory agency." 
• Ipsen indicated in its update that it would analyze the data further before making decisions about the next steps.
• "We will continue to monitor updates from Ipsen regarding the SCLC program," said Gary Crocker, Chairman, and CEO of Merrimack Pharmaceuticals. 
• Ipsen expects to publicly report its top-line data from its continuing Phase 3 study of Onivyde in first-line pancreatic ductal adenocarcinoma before the end of 2022.

https://www.benzinga.com/general/biotech/22/08/28332982/merrimack-pharma-ipsens-cancer-drug-fails-in-overall-survival-measure